Stool Biomarker Kit for IBS Diagnosis via Neurotransmitter Quantification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic tools for irritable bowel syndrome (IBS) are inadequate, particularly in providing positive diagnosis and dietary guidance, as they rely on exclusion methods and do not effectively address the complex interactions between the gut microbiome, brain, and food-related triggers.
Innovation Solution
A kit and method for analyzing stool specimens to quantify neurotransmitters and neuroactive substances such as tryptophan, serotonin, gamma-aminobutyric acid, kynurenic acid, and histamine, using immunological assays or liquid chromatography with mass spectrometry, to determine imbalances that indicate IBS or irritable colon, allowing for targeted dietary interventions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If exclusion diagnostic methods are used to diagnose IBS, then other gastrointestinal diseases can be ruled out, but a positive diagnosis of IBS cannot be achieved
Solution Approach 1:
The patent segments the diagnostic approach into two distinct parts: (1) exclusion diagnostic components that rule out other gastrointestinal diseases using established methods, and (2) a new positive diagnostic component that measures neuroactive substances (serotonin, tryptophan, GABA) in stool samples. This segmentation allows both exclusion and positive diagnosis to coexist without conflict.
Solution Approach 2:
The patent makes the diagnostic system multi-functional by combining multiple diagnostic capabilities in one framework: excluding other gastrointestinal diseases, positively diagnosing IBS through neuroactive substance measurement, and providing dietary guidance based on the results. This universal approach resolves the limitation of exclusion-only methods.
2Ease of operation
If general dietary advice is provided to IBS patients, then patient requests are addressed, but the advice lacks scientific foundation and effectiveness
Solution Approach 1:
The patent implements a feedback mechanism where dietary recommendations are based on actual measured levels of neuroactive substances in the patient's stool. The diagnostic results provide feedback about the patient's specific neuroactive substance imbalances, and dietary advice is tailored accordingly. This creates a closed-loop system where diagnosis directly informs personalized treatment rather than providing generic advice.
Solution Approach 2:
The patent applies local quality by providing customized dietary recommendations specific to each patient's measured neuroactive substance profile. Instead of universal dietary advice, each patient receives targeted guidance based on their individual serotonin, tryptophan, and GABA levels, making the advice locally optimized for their specific condition.
3Reliability
If multiple neuroactive substances are measured in stool samples, then positive diagnosis of IBS is enabled, but diagnostic complexity increases
Solution Approach 1:
The patent merges the measurement of multiple neuroactive substances (serotonin, tryptophan, GABA) into a single integrated diagnostic framework. Rather than treating each substance measurement as a separate complex test, they are combined into one stool sample analysis protocol with unified sampling, processing, and interpretation guidelines, reducing overall complexity.
Solution Approach 2:
The patent uses stool samples as an intermediary medium to indirectly measure neuroactive substance levels in the gut. This mediator approach allows diagnosis without requiring direct access to brain or gut tissue, simplifying the diagnostic process while maintaining reliability through non-invasive sampling.
4Adaptability or versatility
If neuroactive substance levels are quantified to provide dietary guidance, then personalized treatment is achieved, but measurement precision requirements increase
Solution Approach 1:
The patent measures neuroactive substance levels in stool samples, which serve as a copy or proxy for the actual neuroactive substance concentrations in the gut environment. This indirect measurement approach allows personalized dietary guidance without requiring direct, highly precise measurements from more complex sources like tissue biopsies or blood samples.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables a positive diagnosis of IBS and irritable colon by identifying biomarker imbalances in stool, providing a basis for dietary recommendations and symptom relief, improving the management of gastrointestinal disorders.
Implementation Method 1
quantify neurotransmitters and neuroactive substances such as tryptophan, serotonin, gamma-aminobutyric acid, kynurenic acid, and histamine, using immunological assays
Implementation Method 2
liquid chromatography with mass spectrometry
Implementation Method 3
liquid chromatography with mass spectrometry
Data Source
AI summary
Method and kit for diagnosis of irritable bowel syndrome and irritable colon, comprising: a stool extraction system for preparation of a stool extract of substances of the gut-brain-axis, a derivatizing reagent for small biogenic amines; antibodies specific for derivatized tryptophan, serotonin, and GABA; and immunoassay reagents and buffers for combined determination of tryptophan, serotonin, and GABA. The method of in vitro diagnosis of irritable bowel syndrome (IBS) or irritable colon comprises a collecting a specimen of fresh stool; a transfer of the specimen into a stabilizing buffer; an extraction of the biogenic amines (neurotransmitters, neuroactive substances and tissue-active substances) and substances of the gut-brain axis; a combined quantitative analysis for tryptophan, serotonin and GABA, and optionally of histamine and kynurenic acid, to determine any imbalance of substances of the gut-brain-axis and for in vitro diagnosis of irritable bowel syndrome and/or irritable colon based on a comparison respective values and ranges in stools of healthy subjects.